Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service
Internal Medicine Journal · 2026
DOI: 10.1111/imj.70526 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Minn W Chow und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Monash University, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Hyperaldosteronism, Hypertension. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Endocrine Society of Australia and NHMRC Primary Aldosteronism Centre for Excellence, National Health and Medical Research Council, Victorian Government's Operational Infrastructure Scheme.
Abstract (Originalsprache)
Aims
To evaluate the sustained impact of the Endocrine Hypertension Service on primary aldosteronism (PA) diagnosis and management over a subsequent 3‐year period.
Background
PA is a prevalent yet underdiagnosed cause of secondary hypertension, associated with increased cardiovascular, renal and metabolic risk. Limited awareness, resources and expertise contribute to delays in diagnosis and treatment. A dedicated Endocrine Hypertension Service previously improved PA screening and increased primary care referrals in its first 3 years (2016–2019).
Methods
We conducted a retrospective analysis of consecutive new patients seen at a tertiary Endocrine Hypertension Service in Victoria, Australia, from 1 July 2019 to 30 June 2022, including significant COVID‐19 disruptions. Clinical data were analysed by referral year (Y1: 2019/2020, Y2: 2020/2021, Y3: 2021/2022) to assess changes over time.
Results
A total of 457 new patients were assessed, with referrals increasing over time (Y1: 115; Y2: 156; Y3: 186). Most referrals originated from primary care (50%), followed by cardiology (23%). At presentation, 20% of patients were treatment‐naïve, median hypertension duration was 4 years, and 22% had end‐organ damage. Of the cohort, 213 had PA, 171 did not, and 73 were 'undetermined' due to incomplete work‐up. Among 171 patients with PA treated medically, 78% achieved complete biochemical response and 46% complete clinical response on MRA monotherapy, as defined by the Primary Aldosteronism Medical Outcome (PAMO) criteria. Among 34 patients who underwent unilateral adrenalectomy, 86% achieved complete biochemical response and 39% complete clinical response, according to the Primary Aldosteronism Surgical Outcome (PASO) criteria.
Conclusion
Growth in referrals, earlier detection and high treatment response rates highlight the sustained effectiveness of a structured pathway for timely PA diagnosis and management, despite COVID‐19 disruptions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Monash University, Clayton, Victoria, Australia.
- Centre for Endocrinology and Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
- Department of Endocrinology, Monash Health, Clayton, Victoria, Australia.
ORCID-Profile: Minn W Chow, Jimmy Shen, Peter J Fuller, Jun Yang
Förderung
- Endocrine Society of Australia and NHMRC Primary Aldosteronism Centre for Excellence
- National Health and Medical Research Council
- Victorian Government's Operational Infrastructure Scheme
Zitieren
APA
Chow, M. W., Ng, C., Shen, J., Fuller, P. J., Yang, J., & Libianto, R. (2026). Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service. Internal Medicine Journal. https://doi.org/10.1111/imj.70526
Vancouver
Chow MW, Ng C, Shen J, Fuller PJ, Yang J, Libianto R. Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service. Internal Medicine Journal. 2026. doi:10.1111/imj.70526
BibTeX
@article{Chow2026,
author = {Chow, Minn W and Ng, Chrislyn and Shen, Jimmy and Fuller, Peter J and Yang, Jun and Libianto, Renata},
title = {Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70526}
}
EUVIMED